Table A1.
Demographic and Clinical Characteristics of HLA-Matched and -Mismatched Cohorts
| Variable | No. (%) | P | |
|---|---|---|---|
| Matched (n = 1,731) | Mismatched (n = 405) | ||
| Age, years | .13 | ||
| Median | 56 | 55 | |
| Range | 18-77 | 18-73 | |
| Male sex | 1,045 (60) | 231 (57) | |
| KPS, % | .12 | ||
| 90-100 | 1,063 (61) | 253 (62) | |
| < 90 | 574 (33) | 140 (35) | |
| Missing | 94 (5) | 12 (3) | |
| Secondary disorder | .44 | ||
| Yes | 338 (20) | 85 (21) | |
| Missing | 47 (3) | 7 (2) | |
| Cytogenetic status | < .001 | ||
| MK positive | 289 (17) | 52 (13) | |
| Very good | 16 (< 1) | 1 (< 1) | |
| Good | 673 (39) | 134 (33) | |
| Intermediate | 403 (23) | 97 (24) | |
| Poor | 190 (11) | 66 (16) | |
| Very poor | 34 (2) | 5 (1) | |
| Missing | 126 (7) | 50 (12) | |
| Blast in marrow before HCT, % | .06 | ||
| ≤ 2 | 736 (43) | 162 (40) | |
| 2-5 | 357 (21) | 90 (22) | |
| 5-10 | 314 (18) | 73 (18) | |
| > 10 | 135 (8) | 47 (12) | |
| Missing | 189 (11) | 33 (8) | |
| Blast in blood before HCT, % | .10 | ||
| ≤ 3 | 1,325 (77) | 316 (78) | |
| > 3 | 127 (7) | 38 (9) | |
| Missing | 279 (16) | 51 (13) | |
| Platelet count before HCT, × 109/L | .06 | ||
| ≤ 50 | 731 (42) | 197 (49) | |
| > 50 | 993 (57) | 206 (51) | |
| Missing | 7 (< 1) | 2 (< 1) | |
| ANC before HCT, /μL | .71 | ||
| ≥ 800 | 1,029 (59) | 235 (58) | |
| < 800 | 635 (37) | 151 (37) | |
| Missing | 67 (4) | 19 (5) | |
| Elevated LDH before HCT | .58 | ||
| No | 1,023 (59) | 243 (60) | |
| Yes | 492 (28) | 119 (29) | |
| Missing | 216 (12) | 43 (11) | |
| IPSS at diagnosis | .31 | ||
| Low | 41 (2) | 7 (2) | |
| Intermediate-1 | 627 (36) | 130 (32) | |
| Intermediate-2 | 583 (34) | 138 (34) | |
| High | 138 (8) | 34 (8) | |
| Missing | 342 (20) | 96 (24) | |
| Pretransplantation therapy | .71 | ||
| Hypomethylating agents only | 567 (33) | 132 (33) | |
| Chemotherapy only | 104 (6) | 19 (5) | |
| Both | 42 (2) | 7 (2) | |
| None | 971 (56) | 234 (58) | |
| Missing | 47 (3) | 13 (3) | |
| Conditioning regimen intensity | .003 | ||
| Myeloablative | 996 (58) | 215 (53) | |
| Reduced | 543 (31) | 156 (39) | |
| Nonmyeloablative | 159 (9) | 34 (8) | |
| Missing | 33 (2) | 0 | |
| Donor–recipient sex match | .48 | ||
| Male–Male | 693 (40) | 153 (38) | |
| Male–Female | 397 (23) | 89 (22) | |
| Female–Male | 342 (20) | 77 (19) | |
| Female–Female | 281 (16) | 81 (20) | |
| Missing | 18 (1) | 5 (1) | |
| Graft type | .009 | ||
| Bone marrow | 327 (19) | 100 (25) | |
| Peripheral blood | 1,404 (81) | 305 (75) | |
| Ex vivo T-cell depletion | 40 (2) | 13 (3) | .20 |
| ATG or alemtuzumab | 510 (29) | 174 (43) | < .001 |
Abbreviations: ANC, absolute neutrophil count; ATG, antithymocyte globulin; HCT, hematopoietic cell transplantation; IPSS, International Prognostic Scoring System; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; MK, monosomal karyotype.